Back to search results

Observational Study of Liquid Biopsies in Pediatric Solid Tumors

This study is looking at whether traces of a tumor can be found in the blood of children with solid tumors. Researchers will collect blood samples from patients with newly diagnosed or relapsed bone, soft tissue, kidney, thyroid, germ cell, or liver tumors. They will analyze these samples to see if tumor material, like circulating tumor DNA (ctDNA), can be detected. This helps them understand if blood tests can be used to monitor the disease before, during, and after treatment. Healthy individuals under 21 can also participate. The study aims to see if these blood tests are as helpful as traditional methods for tracking the disease over 10 years.

Study design
This is an observational study, meaning participants will not receive new treatments. It plans to enroll 320 participants.
What's involved
You would have blood draws at the start of the study, during disease evaluations, and before and after surgery or radiation.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for detecting circulating tumor DNA is measured at 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05068583

Liquid Biopsies in Pediatric Solid Tumors

Recruiting
Not specifiedAges 6+Observational
Children's Hospital Los Angeles
~320 participants
Updated 2024-08-21 on ClinicalTrials.gov
What's tested:Blood Draw

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To detect circulating tumor DNA (ctDNA) in serial blood samples from patients with pediatric non-CNS solid tumors using low pass whole genome sequencing.
Measured over 10 years

Conditions

Pediatric Solid Tumor, Unspecified, Protocol Specific

Explore related trials

Germ Cell TumorKidney CarcinomaLiver CarcinomaSarcomaSolid NeoplasmThyroid Gland Carcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Fariba Navid, MD · PRINCIPAL_INVESTIGATOR · Children's Hospital Los Angeles

Who to contact

Fariba Navid, MD
[email protected]
323-361-2529
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Newly diagnosed, relapsed, or refractory histologically confirmed high grade bone or soft tissue sarcoma or malignant renal, thyroid, germ cell, or hepatic tumors, OR
Healthy individual with no history of cancer or chronic medical problems and \< 21 years of age

Exclusion

CNS Malignancies
Individuals \< 6 months of age

What this trial measures

  • To detect circulating tumor DNA (ctDNA) in serial blood samples from patients with pediatric non-CNS solid tumors using low pass whole genome sequencing.10 years

    To determine how often circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating tumor RNA (ctRNA) is detected in serial blood samples from patients with newly diagnosed and relapsed/refractory malignant pediatric solid tumors.